Another oral agent has shown promise in a phase IIb trial for relapsing-remitting MS. Ponesimod, a selective sphingosine 1-Phosphate Receptor 1 Agonist, reduced disease burden and activity as assessed by MRI and clinical measures (annualized relapse rates). Safety and tolerability were also assessed and proven to be good. Larger trials are required to confirm the therapeutic utility of ponesimod in RRMS, although choice is always good. Read more in JNNP:
Olsson T, Boster A, Fernández O, Freedman MS, Pozzilli C, Bach D, Berkani O, Mueller MS, Sidorenko T, Radue EW, Melanson M. Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial. J Neurol Neurosurg Psychiatry. 2014 Mar 21. doi: 10.1136/jnnp-2013-307282.
Ponesimod structure- Are the sphingosine wars beginning?